1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane increases expression ISO RGD:1315761 6480464 o, p'-DDT results in increased expression of ADAMTS9 mRNA CTD PMID:19371625 1,2-dimethylhydrazine affects expression ISO RGD:1613350 6480464 1, 2-Dimethylhydrazine affects the expression of ADAMTS9 mRNA CTD PMID:22206623 17alpha-ethynylestradiol increases expression ISO RGD:1315761 6480464 Ethinyl Estradiol results in increased expression of ADAMTS9 mRNA CTD PMID:18936297 17alpha-ethynylestradiol decreases expression EXP 6480464 Ethinyl Estradiol results in decreased expression of ADAMTS9 mRNA CTD PMID:17557909 17beta-estradiol decreases expression ISO RGD:1315761 6480464 Estradiol results in decreased expression of ADAMTS9 mRNA CTD PMID:21185374 17beta-estradiol increases expression ISO RGD:1315761 6480464 Estradiol results in increased expression of ADAMTS9 mRNA CTD PMID:31614463 17beta-estradiol multiple interactions ISO RGD:1315761 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of ADAMTS9 mRNA CTD PMID:20660070 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1315761 6480464 Tetrachlorodibenzodioxin results in increased expression of ADAMTS9 mRNA CTD PMID:20106945 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of ADAMTS9 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of ADAMTS9 mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1613350 6480464 Tetrachlorodibenzodioxin results in increased expression of ADAMTS9 mRNA CTD PMID:29673856 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1315761 6480464 Tetrachlorodibenzodioxin affects the expression of ADAMTS9 mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1613350 6480464 Tetrachlorodibenzodioxin results in decreased expression of ADAMTS9 mRNA CTD PMID:19933214 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of ADAMTS9 mRNA CTD PMID:21346803 2-amino-2-deoxy-D-glucopyranose decreases cleavage ISO RGD:1315761 6480464 Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form CTD PMID:19909832 3,4-dichloroaniline increases expression ISO RGD:1315761 6480464 3, 4-dichloroaniline results in increased expression of ADAMTS9 mRNA CTD PMID:24172598 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1315761 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADAMTS9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADAMTS9 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol increases expression ISO RGD:1613350 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of ADAMTS9 mRNA CTD PMID:30951980 4,4'-sulfonyldiphenol increases methylation ISO RGD:1315761 6480464 bis(4-hydroxyphenyl)sulfone results in increased methylation of ADAMTS9 gene CTD PMID:31601247 4-hydroxyphenyl retinamide increases expression ISO RGD:1613350 6480464 Fenretinide results in increased expression of ADAMTS9 mRNA CTD PMID:28973697 5-fluorouracil multiple interactions ISO RGD:1315761 6480464 TP53 protein affects the reaction [Fluorouracil results in decreased expression of ADAMTS9 mRNA] CTD PMID:15016801 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of ADAMTS9 mRNA CTD PMID:24780913 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of ADAMTS9 mRNA CTD PMID:25825206 7,12-dimethyltetraphene decreases expression ISO RGD:1613350 6480464 9 more ... CTD PMID:32553695 aflatoxin B1 increases expression ISO RGD:1315761 6480464 Aflatoxin B1 results in increased expression of ADAMTS9 mRNA CTD PMID:22100608 aldehydo-D-glucosamine decreases cleavage ISO RGD:1315761 6480464 Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form CTD PMID:19909832 all-trans-retinoic acid increases expression ISO RGD:1315761 6480464 Tretinoin results in increased expression of ADAMTS9 mRNA CTD PMID:23724009 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of ADAMTS9 mRNA CTD PMID:30779732 aristolochic acid A decreases expression ISO RGD:1315761 6480464 aristolochic acid I results in decreased expression of ADAMTS9 mRNA CTD PMID:33212167 benzo[a]pyrene increases expression ISO RGD:1315761 6480464 Benzo(a)pyrene results in increased expression of ADAMTS9 mRNA CTD PMID:20106945 benzo[a]pyrene increases methylation ISO RGD:1315761 6480464 Benzo(a)pyrene results in increased methylation of ADAMTS9 exon, Benzo(a)pyrene results in increased methylation of ADAMTS9 promoter CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:1613350 6480464 Benzo(a)pyrene metabolite results in decreased expression of ADAMTS9 mRNA CTD PMID:32553695 benzo[a]pyrene increases expression ISO RGD:1613350 6480464 Benzo(a)pyrene results in increased expression of ADAMTS9 mRNA CTD PMID:21569818 , PMID:22610609 beta-D-glucosamine decreases cleavage ISO RGD:1315761 6480464 Glucosamine results in decreased cleavage of ADAMTS9 protein alternative form CTD PMID:19909832 bisphenol A increases expression ISO RGD:1315761 6480464 bisphenol A results in increased expression of ADAMTS9 mRNA CTD PMID:19371625 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of ADAMTS9 mRNA CTD PMID:32145629 , PMID:34947998 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of ADAMTS9 mRNA CTD PMID:30816183 bisphenol A increases expression ISO RGD:1613350 6480464 bisphenol A results in increased expression of ADAMTS9 mRNA CTD PMID:30951980 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of ADAMTS9 gene CTD PMID:28505145 bisphenol A multiple interactions ISO RGD:1315761 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADAMTS9 mRNA CTD PMID:28628672 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of ADAMTS9 mRNA CTD PMID:25181051 bisphenol F increases expression ISO RGD:1613350 6480464 bisphenol F results in increased expression of ADAMTS9 mRNA CTD PMID:30951980 buta-1,3-diene increases expression ISO RGD:1613350 6480464 1, 3-butadiene results in increased expression of ADAMTS9 mRNA CTD PMID:29038090 cadmium atom multiple interactions ISO RGD:1315761 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ADAMTS9 mRNA CTD PMID:29741670 cadmium dichloride multiple interactions ISO RGD:1315761 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of ADAMTS9 mRNA CTD PMID:29741670 calcitriol increases expression ISO RGD:1315761 6480464 Calcitriol results in increased expression of ADAMTS9 mRNA CTD PMID:26485663 carbon nanotube affects expression ISO RGD:1613350 6480464 Nanotubes, Carbon analog affects the expression of ADAMTS9 mRNA CTD PMID:25554681 carbon nanotube increases expression ISO RGD:1613350 6480464 Nanotubes, Carbon results in increased expression of ADAMTS9 mRNA CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:1315761 6480464 CGP 52608 promotes the reaction [RORA protein binds to ADAMTS9 gene] CTD PMID:28238834 chlordecone increases expression ISO RGD:1613350 6480464 Chlordecone results in increased expression of ADAMTS9 mRNA CTD PMID:33711761 choline multiple interactions ISO RGD:1613350 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ADAMTS9 mRNA CTD PMID:20938992 crocidolite asbestos affects expression ISO RGD:1315761 6480464 Asbestos, Crocidolite affects the expression of ADAMTS9 mRNA CTD PMID:25757056 Cuprizon increases expression EXP 6480464 Cuprizone results in increased expression of ADAMTS9 mRNA CTD PMID:26577399 Cuprizon decreases expression EXP 6480464 Cuprizone results in decreased expression of ADAMTS9 mRNA CTD PMID:27523638 cyclophosphamide increases expression EXP 6480464 Cyclophosphamide results in increased expression of ADAMTS9 mRNA CTD PMID:27281708 cytarabine decreases expression ISO RGD:1315761 6480464 Cytarabine results in decreased expression of ADAMTS9 mRNA CTD PMID:21198554 dexamethasone increases expression ISO RGD:1315761 6480464 Dexamethasone results in increased expression of ADAMTS9 mRNA CTD PMID:25047013 dexamethasone multiple interactions ISO RGD:1315761 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADAMTS9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADAMTS9 mRNA CTD PMID:28628672 diethylstilbestrol increases expression ISO RGD:1315761 6480464 Diethylstilbestrol results in increased expression of ADAMTS9 mRNA CTD PMID:19371625 dioxygen decreases expression ISO RGD:1315761 6480464 Oxygen deficiency results in decreased expression of ADAMTS9 mRNA CTD PMID:26516004 dioxygen multiple interactions EXP 6480464 [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of ADAMTS9 mRNA CTD PMID:33729688 dioxygen multiple interactions ISO RGD:1613350 6480464 [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ADAMTS9 mRNA CTD PMID:30529165 diuron increases expression ISO RGD:1315761 6480464 Diuron metabolite results in increased expression of ADAMTS9 mRNA CTD PMID:24172598 dorsomorphin multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO RGD:1315761 6480464 Doxorubicin results in decreased expression of ADAMTS9 mRNA CTD PMID:29803840 entinostat decreases expression ISO RGD:1315761 6480464 entinostat results in decreased expression of ADAMTS9 mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA CTD PMID:27188386 epoxiconazole decreases expression ISO RGD:1613350 6480464 epoxiconazole results in decreased expression of ADAMTS9 mRNA CTD PMID:35436446 folic acid multiple interactions ISO RGD:1613350 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ADAMTS9 mRNA CTD PMID:20938992 folic acid decreases expression ISO RGD:1613350 6480464 Folic Acid results in decreased expression of ADAMTS9 mRNA CTD PMID:25629700 furan increases methylation EXP 6480464 furan results in increased methylation of ADAMTS9 gene CTD PMID:22079235 furan increases expression EXP 6480464 furan results in increased expression of ADAMTS9 mRNA CTD PMID:27387713 genistein increases expression ISO RGD:1315761 6480464 Genistein results in increased expression of ADAMTS9 mRNA CTD PMID:19371625 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of ADAMTS9 mRNA CTD PMID:33387578 glycidol decreases expression EXP 6480464 glycidol results in decreased expression of ADAMTS9 mRNA CTD PMID:24915197 hydrogen cyanide increases expression ISO RGD:1613350 6480464 Hydrogen Cyanide results in increased expression of ADAMTS9 mRNA CTD PMID:33914522 hydrogen peroxide affects expression ISO RGD:1315761 6480464 Hydrogen Peroxide affects the expression of ADAMTS9 mRNA CTD PMID:21179406 hydroquinone O-beta-D-glucopyranoside decreases expression ISO RGD:1315761 6480464 Arbutin results in decreased expression of ADAMTS9 mRNA CTD PMID:17103032 indometacin multiple interactions ISO RGD:1315761 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of ADAMTS9 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of ADAMTS9 mRNA CTD PMID:28628672 L-methionine multiple interactions ISO RGD:1613350 6480464 [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of ADAMTS9 mRNA CTD PMID:20938992 methamphetamine increases expression EXP 6480464 Methamphetamine results in increased expression of ADAMTS9 mRNA CTD PMID:19564919 methamphetamine increases expression ISO RGD:1613350 6480464 Methamphetamine results in increased expression of ADAMTS9 mRNA CTD PMID:26307267 methamphetamine multiple interactions EXP 6480464 [Methamphetamine co-treated with SCH 23390] results in increased expression of ADAMTS9 mRNA CTD PMID:19564919 methimazole increases expression EXP 6480464 Methimazole results in increased expression of ADAMTS9 mRNA CTD PMID:30047161 mifepristone decreases expression EXP 6480464 Mifepristone results in decreased expression of ADAMTS9 mRNA CTD PMID:25972201 N-nitrosodiethylamine decreases expression ISO RGD:1315761 6480464 Diethylnitrosamine results in decreased expression of ADAMTS9 mRNA CTD PMID:21527772 nevirapine decreases expression EXP 6480464 Nevirapine metabolite results in decreased expression of ADAMTS9 mRNA, Nevirapine results in decreased expression of ADAMTS9 mRNA CTD PMID:23947594 nickel atom increases expression ISO RGD:1315761 6480464 Nickel results in increased expression of ADAMTS9 mRNA CTD PMID:25583101 octadecanoic acid increases expression ISO RGD:1315761 6480464 stearic acid results in increased expression of ADAMTS9 mRNA CTD PMID:32347412 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of ADAMTS9 mRNA CTD PMID:25729387 oxaliplatin increases expression EXP 6480464 oxaliplatin results in increased expression of ADAMTS9 mRNA CTD PMID:25729387 ozone increases expression EXP 6480464 Ozone results in increased expression of ADAMTS9 mRNA CTD PMID:28623178 paracetamol affects expression ISO RGD:1613350 6480464 Acetaminophen affects the expression of ADAMTS9 mRNA CTD PMID:17562736 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of ADAMTS9 mRNA CTD PMID:33387578 paracetamol increases expression ISO RGD:1315761 6480464 Acetaminophen results in increased expression of ADAMTS9 mRNA CTD PMID:22230336 , PMID:29067470 paracetamol decreases expression ISO RGD:1315761 6480464 Acetaminophen results in decreased expression of ADAMTS9 mRNA CTD PMID:21420995 Phenelzine increases expression ISO RGD:1613350 6480464 Phenelzine results in increased expression of ADAMTS9 mRNA CTD PMID:31249575 phenytoin increases expression EXP 6480464 Phenytoin results in increased expression of ADAMTS9 mRNA CTD PMID:20345932 pirinixic acid increases expression ISO RGD:1613350 6480464 pirinixic acid results in increased expression of ADAMTS9 mRNA CTD PMID:20813756 potassium cyanide increases expression ISO RGD:1613350 6480464 Potassium Cyanide results in increased expression of ADAMTS9 mRNA CTD PMID:33914522 progesterone multiple interactions ISO RGD:1315761 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of ADAMTS9 mRNA CTD PMID:20660070 progesterone increases expression ISO RGD:1315761 6480464 Progesterone results in increased expression of ADAMTS9 mRNA CTD PMID:21540246 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of ADAMTS9 mRNA CTD PMID:28374803 SB 431542 multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 SCH 23390 multiple interactions EXP 6480464 [Methamphetamine co-treated with SCH 23390] results in increased expression of ADAMTS9 mRNA CTD PMID:19564919 SCH 23390 decreases expression EXP 6480464 SCH 23390 results in decreased expression of ADAMTS9 mRNA CTD PMID:19564919 serpentine asbestos increases expression ISO RGD:1315761 6480464 Asbestos, Serpentine results in increased expression of ADAMTS9 mRNA CTD PMID:24160326 silicon dioxide increases expression ISO RGD:1613350 6480464 Silicon Dioxide results in increased expression of ADAMTS9 mRNA CTD PMID:23221170 silicon dioxide decreases methylation ISO RGD:1315761 6480464 Silicon Dioxide results in decreased methylation of ADAMTS9 gene CTD PMID:34973136 silver atom decreases expression ISO RGD:1315761 6480464 Silver results in decreased expression of ADAMTS9 mRNA CTD PMID:26551752 silver atom decreases expression ISO RGD:1613350 6480464 Silver results in decreased expression of ADAMTS9 mRNA CTD PMID:27131904 silver(0) decreases expression ISO RGD:1315761 6480464 Silver results in decreased expression of ADAMTS9 mRNA CTD PMID:26551752 silver(0) decreases expression ISO RGD:1613350 6480464 Silver results in decreased expression of ADAMTS9 mRNA CTD PMID:27131904 sodium arsenate increases expression ISO RGD:1613350 6480464 sodium arsenate results in increased expression of ADAMTS9 mRNA CTD PMID:21795629 sodium arsenite affects methylation ISO RGD:1315761 6480464 sodium arsenite affects the methylation of ADAMTS9 gene CTD PMID:28589171 sodium arsenite increases expression ISO RGD:1315761 6480464 sodium arsenite results in increased expression of ADAMTS9 mRNA CTD PMID:29301061 Soman increases expression EXP 6480464 Soman results in increased expression of ADAMTS9 mRNA CTD PMID:19281266 sunitinib decreases expression ISO RGD:1315761 6480464 Sunitinib results in decreased expression of ADAMTS9 mRNA CTD PMID:31533062 thapsigargin decreases expression ISO RGD:1315761 6480464 Thapsigargin results in decreased expression of ADAMTS9 mRNA CTD PMID:22378314 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of ADAMTS9 mRNA CTD PMID:34492290 titanium dioxide affects expression ISO RGD:1613350 6480464 titanium dioxide affects the expression of ADAMTS9 mRNA CTD PMID:23557971 titanium dioxide decreases expression EXP 6480464 titanium dioxide results in decreased expression of ADAMTS9 mRNA CTD PMID:30012374 titanium dioxide decreases expression ISO RGD:1613350 6480464 titanium dioxide results in decreased expression of ADAMTS9 mRNA CTD PMID:27760801 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of ADAMTS9 mRNA CTD PMID:25729387 topotecan increases expression EXP 6480464 Topotecan results in increased expression of ADAMTS9 mRNA CTD PMID:25729387 trichloroethene decreases expression EXP 6480464 Trichloroethylene results in decreased expression of ADAMTS9 mRNA CTD PMID:33387578 trichostatin A decreases expression ISO RGD:1315761 6480464 trichostatin A results in decreased expression of ADAMTS9 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA CTD PMID:27188386 triphenyl phosphate decreases expression EXP 6480464 triphenyl phosphate results in decreased expression of ADAMTS9 mRNA CTD PMID:30589522 tunicamycin decreases expression ISO RGD:1315761 6480464 Tunicamycin results in decreased expression of ADAMTS9 mRNA CTD PMID:22378314 valdecoxib decreases expression EXP 6480464 valdecoxib results in decreased expression of ADAMTS9 mRNA CTD PMID:24136188 valproic acid increases expression ISO RGD:1613350 6480464 Valproic Acid results in increased expression of ADAMTS9 mRNA CTD PMID:24896083 valproic acid multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:1315761 6480464 Valproic Acid results in decreased expression of ADAMTS9 mRNA CTD PMID:23179753 , PMID:26272509 vorinostat multiple interactions ISO RGD:1315761 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAMTS9 mRNA CTD PMID:27188386 zearalenone increases expression ISO RGD:1315761 6480464 Zearalenone results in increased expression of ADAMTS9 mRNA CTD PMID:19371625 zearalenone decreases expression EXP 6480464 Zearalenone results in decreased expression of ADAMTS9 mRNA CTD PMID:17557909 zoledronic acid increases expression ISO RGD:1315761 6480464 zoledronic acid results in increased expression of ADAMTS9 mRNA CTD PMID:24714768
